Histone Chaperones
-
Subject Areas on Research
- A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
- All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae.
- Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
- Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.
- Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
- Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
- Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
- Neurabins recruit protein phosphatase-1 and inhibitor-2 to the actin cytoskeleton.
- Protein phosphatase 1 regulation by inhibitors and targeting subunits.
- Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding.
- SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
- SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
- Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
- Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
- Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
- The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
- Transcriptional trans activators of human and simian foamy viruses contain a small, highly conserved activation domain.